Health Care & Life Sciences » Pharmaceuticals » Top pharmaceutical drugs | Top anti-rheumatic products by revenue globally 2017 and 2024

Top worldwide anti-rheumatics by revenue 2017 and 2024

Top anti-rheumatic products based on global revenue in 2017 and 2024 (Figures expressed in millions of U.S. dollars, unless otherwise specified)

The data shows the top anti-rheumatics worldwide by revenue in 2017 and a projection for 2024. Enbrel, a drug developed by Pfizer, Amgen, and Takeda, is expected to generate some four billion USD in revenue in 2024. Anti-rheumatic drugs is used to treat and slow the progress of rheumatoid arthritis. Rheumatoid arthritis is an autoimmune disease that principlally attacks the joints but also impacts tissues and organs.

Anti-rheumatic products Some of the top anti-rheumatic products in the world include J&J, Merck & Co.

Humira (AbbVie, Eisai) 18922 15233
Enbrel (Pfizer, Amgen, Takeda) 8241 4072
Simponi (J&J, Merck) 2652 2845
Otezla (Celgene) 1279 2621
Upadacitinib (AbbVie) 2570